Corogen Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 261.42%
- Ebitda 5173.21%
- Net Worth 17.43%
- Total Assets 239.02%
About Corogen Pharma
Corogen Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 August 1997 and has a history of 27 years and five months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Zainab Fatepurwala and Shabnam Rangwala serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U28231GJ1997PTC032842
-
Company No.
032842
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Aug 1997
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Corogen Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zainab Fatepurwala
|
Director | 30-May-2024 | Current |
|
Shabnam Rangwala
|
Director | 30-May-2024 | Current |
Financial Performance of Corogen Pharma.
Corogen Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 261.42% increase in profit. The company's net worth Soared by an impressive increase of 17.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corogen Pharma?
Unlock access to Corogen Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Unisafe Bioscience Private LimitedZainab Fatepurwala and Shabnam Rangwala are mutual person
-
Civanta Distributors Private LimitedZainab Fatepurwala and Shabnam Rangwala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Corogen Pharma?
Unlock and access historical data on people associated with Corogen Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corogen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corogen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
